华森制药：HSN002066C1片获临床试验批准

Core Viewpoint - Huason Pharmaceutical announced that HSN002066C1 tablets have received the "Drug Clinical Trial Approval Notice" from the National Medical Products Administration, allowing clinical trials for advanced malignant solid tumors [1] Group 1 - The drug HSN002066C1 is classified as a Class 1.1 new drug [1] - The application numbers for the approval are CXHL2501398 and CXHL2501399 [1] - The indication for HSN002066C1 is for advanced malignant solid tumors, and it is approved for monotherapy in clinical trials [1]